Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Group 1 - Acrivon Therapeutics, Inc. (ACRV) has outperformed its Medical sector peers with a year-to-date performance increase of 42.7%, compared to the average gain of 8.6% for Medical stocks [2][3] - Acrivon Therapeutics currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [2][3] - The Zacks Consensus Estimate for ACRV's full-year earnings has increased by 4.9% over the past quarter, reflecting improved analyst sentiment [2] Group 2 - Acrivon Therapeutics is part of the Medical - Drugs industry, which consists of 178 individual stocks and currently ranks 93 in the Zacks Industry Rank [3] - The average performance of stocks in the Medical - Drugs industry has been a loss of 3.5% this year, highlighting ACRV's relative strength [3] - Akebia Therapeutics (AKBA) is another stock in the Medical sector that has shown strong performance, with a year-to-date return of 8.9% and a Zacks Rank of 2 (Buy) [2][3]